Compare · FLDM vs WAT
FLDM vs WAT
Side-by-side comparison of Fluidigm Corporation (FLDM) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- FLDM operates in Capital Goods, while WAT operates in Industrials - the two are in different parts of the market.
- WAT is the larger of the two at $19.34B, about 79.1x FLDM ($244.6M).
- WAT has hit the wire 8 times in the past 4 weeks while FLDM has been quiet.
- WAT has more recent analyst coverage (25 ratings vs 0 for FLDM).
- Company
- Fluidigm Corporation
- Waters Corporation
- Price
- $3.70-7.27%
- $309.80-0.45%
- Market cap
- $244.6M
- $19.34B
- 1M return
- -
- +2.49%
- 1Y return
- -
- -8.90%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2011
- 1995
- News (4w)
- 0
- 8
- Recent ratings
- 0
- 25
Fluidigm Corporation
Fluidigm Corporation creates, manufactures, and markets technologies and life sciences tools worldwide. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, Hyperion tissue imager, and flow conductor; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow., as well as Maxpar direct immune profiling assays and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 system, Polaris system, C1 IFCs, and Polaris IFC. Fluidigm Corporation sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Fluidigm Corporation has a collaboration agreement with the Karolinska Institutet for research applications and product development utilizing CyTOF XT. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest FLDM
- No More Free COVID-19 At-Home Tests, Federal Government Says
- Fluidigm Corporation filed SEC Form 8-K: Leadership Update
- Fluidigm Corporation filed SEC Form 8-K: Leadership Update
- SEC Form 4: Colston Bill was granted 30,914 shares, increasing direct ownership by 109% to 59,288 units
- SEC Form 4: Burbach Gerhard F was granted 30,914 shares, increasing direct ownership by 47% to 96,827 units
- SEC Form 4: Madaus Martin D was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Witney Frank was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Paya Carlos V was granted 30,914 shares, increasing direct ownership by 44% to 100,468 units
- SEC Form 4: Casdin Eli was granted 30,914 shares, increasing direct ownership by 195% to 46,766 units
- SEC Form 4: Clague Laura was granted 30,914 shares, increasing direct ownership by 65% to 78,415 units
Latest WAT
- Amendment: SEC Form SCHEDULE 13G/A filed by Waters Corporation
- Waters Corporation Schedules First Quarter 2026 Earnings Conference Call
- Waters Debuts Industry-First Extended-Range MALS Detector for UHPLC/UPLC, Powering Rapid Characterization of Large Molecules
- SEC Form DEFA14A filed by Waters Corporation
- SEC Form DEF 14A filed by Waters Corporation
- Waters Announces FDA Clearance of the Most Comprehensive At-Home Cervical Cancer Screening Tool, the Onclarity HPV Self-Collection Kit and FDA-Approved HPV Assay
- SEC Form 4 filed by Bennett Jianqing
- Waters upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Jiang Wei
- SEC Form 4 filed by Knight Heather